Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | ADH1B | P00325 | 1/20 | 0.30 |
| ▸ | ADH1C | P00326 | 1/20 | 0.30 |
| ▸ | ADH1A | P07327 | 1/20 | 0.30 |
| ▸ | ADH4 | P08319 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9004375 | 1.00 | ALDH1A1 (0.32) | ALDH1A1HSD17B10ADH1BADH1CADH1A | |
| SCHEMBL11001515 | 0.96 | ALDH1A1 (0.33) | ALDH1A1HSD17B10ADH1BADH1CADH1A | |
| SCHEMBL22033682 | 0.96 | ALDH1A1 (0.33) | ALDH1A1HSD17B10ADH1BADH1CADH1A | |
| SCHEMBL1524657 | 0.96 | ALDH1A1 (0.33) | ALDH1A1HSD17B10ADH1BADH1CADH1A | |
| SCHEMBL1173999 | 0.96 | ALDH1A1 (0.33) | ALDH1A1HSD17B10ADH1BADH1CADH1A | |
| SCHEMBL6101790 | 0.96 | ALDH1A1 (0.33) | ALDH1A1HSD17B10ADH1BADH1CADH1A | |
| SCHEMBL10494046 | 0.96 | ALDH1A1 (0.33) | ALDH1A1HSD17B10ADH1BADH1CADH1A | |
| SCHEMBL22033837 | 0.96 | ALDH1A1 (0.33) | ALDH1A1HSD17B10ADH1BADH1CADH1A | |
| SCHEMBL984941 | 0.96 | — | — | |
| SCHEMBL491425 | 0.92 | ALDH1A1 (0.36) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090143370-A1 | Non-nucleoside Reverse Transcriptase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-04 | — | — | US | claimed |
| EP-1756091-A1 | NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2007-02-28 | — | — | EP | claimed |
| JP-2007501189-A | — | — | 2007-01-25 | — | — | JP | claimed |
| EP-1651631-A1 | BICYCLIC IMIDAZOL DERIVATIVES AGAINST FLAVIVIRIDAE | GENELABS TECHNOLOGIES, INC. (US) | 2006-05-03 | — | — | EP | claimed |
| US-20050282907-A1 | Non nucleoside reverse transcriptase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-12-22 | — | — | US | claimed |
| WO-2005118575-A1 | NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-12-15 | — | — | WO | claimed |
| WO-2005012288-A1 | BICYCLIC IMIDAZOL DERIVATIVES AGAINST FLAVIVIRIDAE | GENELABS TECHNOLOGIES, INC (US) | 2005-02-10 | — | — | WO | claimed |
| CN-115068468-A | Carboxylic aromatic amides as bradykinin B1 receptor antagonists | 拜耳制药股份公司 | 2022-09-20 | — | — | CN | disclosed |
| WO-2016087593-A1 | NOVEL FUNGICIDAL QUINOLINYLAMIDINES | SYNGENTA PARTICIPATIONS AG (CH) | 2016-06-09 | — | — | WO | disclosed |
| US-8198458-B2 | Non-nucleoside reverse transcriptase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-12 | — | — | US | disclosed |
| US-20090143370-A1 | Non-nucleoside Reverse Transcriptase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-04 | — | — | US | disclosed |
| US-7517998-B2 | Benzothiazole or benzothiazine derivative of dipyrido(2,3;b:2',3'-e) diazepin-6-one; viricide against human t-cell leukemia/lymphoma virus | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2009-04-14 | — | — | US | disclosed |
| EP-1756091-A1 | NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2007-02-28 | — | — | EP | disclosed |
| US-20050282907-A1 | Non nucleoside reverse transcriptase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-12-22 | — | — | US | disclosed |
| WO-2005118575-A1 | NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-12-15 | — | — | WO | disclosed |
| US-5795905-A | 3-AMINO-5-PHENYL-1,2,4-TRIAZOLES | NEUROCRINE BIOSCIENCES, INC. (US) | 1998-08-18 | — | — | US | disclosed |
| EP-0846108-A1 | AMINO-SUBSTITUTED THIADIAZOLES, PYRIMIDINES, TRIAZINES OR TRIAZOLES USEFUL AS CTF RECEPTOR ANTAGONISTS | NEUROCRINE BIOSCIENCES, INC. (US) | 1998-06-10 | — | — | EP | disclosed |
| US-5719296-A | THERAPY, PREVENTION OF AUTOIMMUNE DISEASES; PREVENTS PEPTIDE BINDING TO MAJOR HISTOCOMPATBILITY COMPLEX PROTEINS | MERCK & CO., INC. (US) | 1998-02-17 | — | — | US | disclosed |
| WO-1997016425-A1 | NOVEL INHIBITORS OF PEPTIDE BINDING TO MHC CLASS II PROTEINS | MERCK & CO., INC. (US) | 1997-05-09 | — | — | WO | disclosed |
| WO-1996039400-A1 | AMINO-SUBSTITUTED THIADIAZOLES, PYRIMIDINES, TRIAZINES OR TRIAZOLES USEFUL AS CTF RECEPTOR ANTAGONISTS | NEUROCRINE BIOSCIENCES, INC. (US) | 1996-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282907-A1 | Non nucleoside reverse transcriptase inhibitors | POLR1A, RTF1, POLR1E | ALDH1A1 382/4885HSD17B10 490/4885ADH1B 243/4885 |
| US-20090143370-A1 | Non-nucleoside Reverse Transcriptase Inhibitors | RTF1, POLR1A, POLR1E | ALDH1A1 411/4885HSD17B10 417/4885ADH1B 220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.